Success Metrics

Clinical Success Rate

37.5%

Based on 3 completed trials

Completion Rate

38%(3/8)

Active Trials

0(0%)

Results Posted

267%(8 trials)

Terminated

5(63%)

Phase Distribution

Ph phase_1

13%

Ph phase_2

63%

Ph phase_3

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

1(12.5%)

Phase 2Efficacy & side effects

5(62.5%)

Phase 3Large-scale testing

2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

37.5%

3 of 8 finished

Non-Completion Rate

62.5%

5 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(5)

Detailed Status

Terminated5

Completed3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

37.5%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (12.5%)

Phase 25 (62.5%)

Phase 32 (25.0%)

Trials by Status

terminated563%

completed338%

Recent Activity

0 active trials

Showing 5 of 8

terminatedphase_3

Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

NCT04784559

terminatedphase_2

Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)

NCT05705167

terminatedphase_2

Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial

NCT01876043

terminatedphase_2

Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide

NCT03117361

completedphase_3

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

NCT01102426

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT04784559Phase 3

Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

Terminated

NCT05705167Phase 2

Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)

Terminated

NCT01876043Phase 2

Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial

Terminated

NCT03117361Phase 2

Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide

Terminated

NCT01102426Phase 3

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

Completed

NCT03070964Phase 2

A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

Terminated

NCT02100657Phase 1

Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma

Completed

NCT00229203Phase 2

A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma